March 01, 2023

5 Trends to Watch: 2023 Medical Device Industry

You've Reached Your
Free Article Limit This Month
Register for free to get unlimited access to all OnPractice content.
Register Now
  1. Investment Continues in Medical Devices and Technology - The challenging economy during the last year has slowed the pace of investment and lowered valuations, but investors still have money and a willingness to invest in new technologies addressing unmet medical needs. Venture capital (VC), private equity (PE), and strategic investors continue to look for opportunities to capitalize on and steer development of next generation medical treatments.

  2. Due Diligence for Investment and Acquisitions Goes Deeper - The most common medtech exit last year was M&A, and M&A momentum will continue in 2023. The medtech giants have lots of cash and will be looking to acquire or invest in innovative or bolt-on technologies that can drive revenue. Potential targets should de-risk their commercial, regulatory and IP strategies and be prepared for deeper scrutiny during due diligence.

  3. The Rise of AI and Connected Devices - Artificial intelligence (AI) is having a bigger impact on medical devices in the delivery of treatments, R&D, clinical trials, data collection, and personalized medicine. Connected devices and telehealth continue to change the delivery of healthcare.

  4. Intellectual Property (IP) Is Critical for MedTech Innovations - The pace of innovation in medtech continues to accelerate, as does the importance of IP. Strategic companies should use patents, trademarks, and trade secrets to protect innovations and gain a competitive edge. In uncertain times, collaborations can help advance technology in a de-risked manner. Strategic managing of IP provides an advantage for weathering a stormy market. 

  5. Beware of Data Breaches, Hacking, and Lawsuits - Hacking of digital medical devices, data security and privacy of patient info are top concerns. In today's uncertain economy, expect an uptick in litigation from personal injury and commercial disputes to consumer class actions focused on data, privacy or enforcement activity by the FDA or other agencies. Making choices that strengthen your access to legal defenses and demonstrate proper responses to issues when they arise remains key.

ALM expressly disclaims any express or implied warranty regarding the OnPractice Content, including any implied warranty that the OnPractice Content is accurate, has been corrected or is otherwise free from errors.

More From Greenberg Traurig

The New York Court of Appeals: A Triumph of Merit Selection

By Henry M. Greenberg Greenberg Traurig May 25 , 2023

The current court is a triumph of the merit selection process that New Yorkers voted for in 1977.

Attorney Fees Awards Under the Clean Streams Law

By David Mandelbaum Greenberg Traurig May 24 , 2023

In February, the Pennsylvania Supreme Court decided that the Environmental Hearing Board could award attorney fees and litigation costs to a prevailing third-party appellant under the Clean Streams Law.

GT's The Performance Review Episode 20: All Secrets Revealed: Employee Investigations

By Philip I. Person Greenberg Traurig May 24 , 2023

In this episode, Sue Ann Van Dermyden, co-founder and senior partner at one of the nation’s top investigations firms, joins Philip Person and Ryan Bykerk to discuss the ins and outs of employee investigations.

More From Health Care

Welcome Chris Salmen

By Christopher Salmen McDermott Will & Emery May 24 , 2023

Chris Salmen joined McDermott+Consulting earlier this month as a senior director, bringing his unique blend of medical device, diagnostic and digital health experience to advise clients on their go-to-market strategy.

Debt Limit Deadlock Continues

By Debra Curtis McDermott Will & Emery May 22 , 2023

Debbie Curtis and Rodney Whitlock discuss what the debt limit deadlock means for healthcare stakeholders as the June 1 deadline draws closer.

McDermottPlus Check-Up: May 19, 2023

By Debra Curtis McDermott Will & Emery May 19 , 2023

The House and Senate were both in session this week, with significant healthcare activity at the committee level.

Featured Stories